Marker Therapeutics, Inc. announced a private placement agreement expected to generate gross proceeds of $16.1 million, before deducting associated fees and expenses. This financing round saw participation from both new and existing investors, including Blue Owl Healthcare Opportunities, New Enterprise Associates (NEA), and Aisling Capital.
The company is selling 5,031,250 shares of its common stock, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of shares. The purchase price was set at $3.20 per share or $3.199 per pre-funded warrant, with accompanying warrants exercisable at $4.03 per share.
Proceeds from this financing are earmarked to support the clinical advancement of the company’s Phase 1 APOLLO study, which is investigating MT-601 in lymphoma patients. This capital infusion is critical for collecting additional clinical data and progressing Marker's lead clinical asset.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.